Cargando…

FIB-4 is closer to FibroScan screen results to detecting advanced liver fibrosis and maybe facilitates NAFLD warning

To assess the relationship between clinical biochemical characteristics and steatosis or fibrosis by Fibroscan in non-alcoholic fatty liver disease (NAFLD) patients in order to seek the simple effective screening method closed to the results of the fibroScan measurement. A cross-sectional study was...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ding, Yuping, Wang, Zuoyu, Niu, Haiyan, Deng, Quanjun, Wang, Yanan, Xia, Shihai
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Lippincott Williams & Wilkins 2023
Materias:	4500
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10470683/ https://www.ncbi.nlm.nih.gov/pubmed/37653822 http://dx.doi.org/10.1097/MD.0000000000034957

Ejemplares similares

Accuracy of FibroScan in analysis of liver fibrosis in patients with concomitant chronic Hepatitis B and nonalcoholic fatty liver disease
por: Li, Qiang, et al.
Publicado: (2020)

Serum uric acid to creatinine ratio is associated with higher prevalence of NAFLD detected by FibroScan in the United States
por: Wang, Rusha, et al.
Publicado: (2022)

Enhanced diagnosis of advanced fibrosis and cirrhosis in individuals with NAFLD using FibroScan-based Agile scores
por: Sanyal, Arun J., et al.
Publicado: (2023)

Diagnostic Accuracy of FibroScan and Factors Affecting Measurements
por: Oeda, Satoshi, et al.
Publicado: (2020)

The discriminatory ability of FibroScan liver stiffness measurement, controlled attenuation parameter, and FibroScan–aspartate aminotransferase to predict severity of liver disease in children
por: Chaidez, Alexander, et al.
Publicado: (2022)

Comparison of ELF, FibroTest and FibroScan for the non-invasive assessment of liver fibrosis
por: Friedrich-Rust, Mireen, et al.
Publicado: (2010)

A Comparative Analysis of the APRI, FIB4, and FibroScan Score in Evaluating the Severity of Chronic Liver Disease in Chronic Hepatitis B Patients in India
por: Rungta, Sumit, et al.
Publicado: (2021)

Prospective Comparison of Transient Elastography Using Two Different Devices: Performance of FibroScan and FibroTouch
por: Serra, Joao Tiago, et al.
Publicado: (2020)

Diagnostic Accuracy of APRI, AAR, FIB-4, FI, King, Lok, Forns, and FibroIndex Scores in Predicting the Presence of Esophageal Varices in Liver Cirrhosis: A Systematic Review and Meta-Analysis
por: Deng, Han, et al.
Publicado: (2015)

AST/ALT ratio, APRI, and FIB-4 compared to FibroScan for the assessment of liver fibrosis in patients with chronic hepatitis B in Bandar Abbas, Hormozgan, Iran
por: Moosavy, Seyed Hamid, et al.
Publicado: (2023)

The clinical utility of FibroScan(®) as a noninvasive diagnostic test for liver disease
por: Wilder, Julius, et al.
Publicado: (2014)

Points to Be Considered When Applying FibroScan S Probe in Children With Biliary Atresia
por: Kim, Seung, et al.
Publicado: (2014)

A prospective comparative assessment of the accuracy of the FibroScan in evaluating liver steatosis
por: Jun, Baek Gyu, et al.
Publicado: (2017)

Liver Stiffness Measurement With FibroScan: Use the Right Probe in the Right Conditions!
por: Berger, Arthur, et al.
Publicado: (2019)

Estimation of Liver Fat by FibroScan in Patients With Nonalcoholic Fatty Liver Disease
por: Shrestha, Rupesh, et al.
Publicado: (2021)

The role of FibroScan in the era of metabolic (dysfunction)-associated fatty liver disease
por: Yilmaz, Yusuf, et al.
Publicado: (2023)

FIB-4, APRI, and AST/ALT ratio compared to FibroScan for the assessment of hepatic fibrosis in patients with non-alcoholic fatty liver disease in Bandar Abbas, Iran
por: Amernia, Behnaz, et al.
Publicado: (2021)

Safety Profile of Liver FibroScan in Patients with Cardiac Pacemakers or Implantable Cardioverter-Defibrillators
por: Chan, Yin, et al.
Publicado: (2017)

Correlates of hepatic stiffness by FibroScan(©) in a multicentric Italian cohort of HIV-infected patients
por: Tarquini, P, et al.
Publicado: (2010)

Use of aspartate aminotransferase to platelet ratio to reduce the need for FibroScan in the evaluation of liver fibrosis
por: Wong, Stephanie, et al.
Publicado: (2017)

FibroScan Detection of Fatty Liver/Liver Fibrosis in 2266 Cases of Chronic Hepatitis B
por: He, Tingshan, et al.
Publicado: (2020)

Clinical Classification of Obesity and Implications for Metabolic Dysfunction-Associated Fatty Liver Disease and Treatment
por: Ding, Yuping, et al.
Publicado: (2023)

Diagnostic accuracy of transient elastography (FibroScan) in detection of esophageal varices in patients with cirrhosis: A meta-analysis
por: Pu, Ke, et al.
Publicado: (2017)

Direct comparison of the FibroScan XL and M probes for assessment of liver fibrosis in obese and nonobese patients
por: Durango, Esteban, et al.
Publicado: (2013)

Liver Biopsy and FibroScan to Detect Early Histopathological Changes in Chronic HBV Patients Not Candidate for Treatment
por: Maklad, Sahar, et al.
Publicado: (2014)

Validation of Novel Fibrosis Index (NFI) for assessment of liver fibrosis: comparison with transient elastography (FibroScan)
por: Hussain, Azhar, et al.
Publicado: (2019)

The association of weight gain with nonalcoholic fatty liver disease and fibrosis detected by FibroScan in the United States
por: Wijarnpreecha, Karn, et al.
Publicado: (2022)

Effect of FibroScan test in antiviral therapy for HBV-infected patients with ALT <2 upper limit of normal
por: Han, Xian-Zhi, et al.
Publicado: (2020)

Value of anti-p53 antibody as a biomarker for hepatocellular carcinoma: Evidence from a meta-analysis
por: Chang, Yue, et al.
Publicado: (2020)

Validation of Controlled Attenuation Parameter Measured by FibroScan as a Novel Surrogate Marker for the Evaluation of Metabolic Derangement
por: Huang, Zhimin, et al.
Publicado: (2022)

Clinical relevance of lipid panel and aminotransferases in the context of hepatic steatosis and fibrosis as measured by transient elastography (FibroScan®)
por: Chi-Cervera, Luis Alberto, et al.
Publicado: (2021)

Utility of FibroScan-based scoring systems to narrow the risk group of nonalcoholic fatty liver disease with comorbidities
por: Miura, Kouichi, et al.
Publicado: (2022)

Transient Elastography is Superior to FIB-4 in Assessing the Risk of Hepatocellular Carcinoma in Patients With Chronic Hepatitis B
por: Kim, Seung Up, et al.
Publicado: (2016)

Performance of liver stiffness measurements obtained with FibroScan is affected by glucose metabolism in patients with nonalcoholic fatty liver disease
por: Yang, Xinyu, et al.
Publicado: (2021)

Elevated liver fibrosis index FIB-4 is not reliable for HCC risk stratification in predominantly non-Asian CHB patients
por: Demir, Münevver, et al.
Publicado: (2016)

Accuracy of transient elastography-FibroScan(®), acoustic radiation force impulse (ARFI) imaging, the enhanced liver fibrosis (ELF) test, APRI, and the FIB-4 index compared with liver biopsy in patients with chronic hepatitis C
por: Ragazzo, Taisa Grotta, et al.
Publicado: (2017)

Feasibility study and reference values of FibroScan 502 with M probe in healthy preschool children aged 5 years
por: Zeng, Jing, et al.
Publicado: (2019)

Comparing the controlled attenuation parameter using FibroScan and attenuation imaging with ultrasound as a novel measurement for liver steatosis
por: Hsu, Po-Ke, et al.
Publicado: (2021)

The FibroScan-aspartate aminotransferase score can stratify the disease severity in a Japanese cohort with fatty liver diseases
por: Fujii, Hideki, et al.
Publicado: (2021)

Correlation between Cumulative Methotrexate Dose, Metabolic Syndrome and Hepatic Fibrosis Detected by FibroScan in Rheumatoid Arthritis Patients
por: Lertnawapan, Ratchaya, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_m5ml4ao4f7ho708t2hje42d90r